Original Publication Date: 21 November, 2013
Publication / Source: Lung Cancer Management
Authors: Ashish Sangal & Glen J Weiss
Often in clinical practice, dose modifications in the form of dose reductions or delays are warranted in response to treatment-related toxicity with systemic therapy administration [1,2]. However, this practice may raise concern about its impact on therapeutic benefit. Current guidelines from the National Comprehensive Cancer Network favor administration of systemic therapy (depending on the line) for patients with advanced-stage non-small-cell lung cancer (NSCLC) in good performance status, independent of their age.